Physician profile
Nicole A Turgeon
NPI 1972594109
$129,914.96
in general payments reported to CMS, 2019-2025
2 companies · $41K in 2025
The $41K reported for 2025 was more than what 97% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,390 · 2022: $13K · 2023: $11K · 2024: $62K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $76K · Travel and Lodging: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $76,420.83 |
| Travel and Lodging | $20,071.63 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,625.00 |
| Food and Beverage | $694.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $98,922.34 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $30,992.62 | 2024 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Turgeon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.